非裔美国人肾病与高血压研究中尿酸轨迹与CKD进展的关系
该研究基于AASK队列1094例非裔美国人CKD患者,随访至多12年,采用Cox比例风险模型分析尿酸轨迹与复合ESKD结局的关联。结果显示,与正常上升组相比,高稳定组、高上升组和极高稳定组的复合ESKD风险均显著升高,且极高稳定组风险高于高下降组。调整APOL1风险等位基因、降压药类型和平均动脉压目标后关联未改变。
要点
- 尿酸轨迹与ESKD风险相关,极高稳定组风险最高(HR=3.21)。
- 动态监测尿酸变化有助于评估CKD进展中的ESKD风险。
- 调整APOL1、降压药及血压目标后,尿酸轨迹与ESKD关联未变。
核心结论
- 在非裔美国人CKD患者中,尿酸轨迹与ESKD发生率相关。
- 追踪尿酸随时间的变化可改善对CKD进展中ESKD风险的评估。
研究设计与样本
- AASK队列研究,纳入1094例eGFR降低的非裔美国人,随访至多12年。
- 使用Cox比例风险模型分析尿酸轨迹与复合ESKD结局的关联。
主要发现
- 与正常上升组相比,高稳定组复合ESKD风险HR=2.28(P=0.012)。
- 与正常上升组相比,高上升组复合ESKD风险HR=1.95(P=0.042)。
- 与正常上升组相比,极高稳定组复合ESKD风险HR=3.21(P<0.001)。
- 极高稳定组ESKD风险高于高下降组(HR=1.98,P=0.046)。
- 调整APOL1风险等位基因、降压药类型和平均动脉压目标后关联未改变。
临床怎么用
- 在非裔美国人CKD患者中,可动态监测尿酸轨迹以辅助评估ESKD风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Serum uric acid levels increase with progressive kidney disease, and chronic elevations may contribute to chronic kidney disease (CKD) progression. We analyzed data from the African American Study of Kidney Disease and Hypertension (AASK) to examine the hypothesis that individuals with declining serum urate levels during follow-up would experience slower loss of kidney function. METHODS: The AASK recruited 1094 African-American individuals with reduced estimated glomerular filtration rate (eGFR) and followed up with them for up to 12 years. The eGFR and defined end-stage kidney disease (ESKD) composite score were used to establish CKD stages. We employed a Cox proportional hazards model to investigate the association between uric acid trajectories and the composite ESKD outcome. RESULTS: Compared with the normo-increasing uric acid group (i.e., those who had the lowest overall serum uric acid levels), the high-stable (hazard ratio [HR] = 2.28, P = 0.012), the high-increasing (HR = 1.95, P = 0.042), and extremely high-stable (HR = 3.21, P < 0.001) uric acid groups had higher risk of the composite ESKD outcome. The extremely high-stable group also had a greater ESKD risk than the high-decreasing group (HR = 1.98, P = 0.046). Adjustment for APOL1 risk allele, antihypertensive drug type, and mean arterial pressure treatment target did not alter the relationship between uric acid trajectories and the composite ESKD outcome. CONCLUSION: Uric acid trajectories are associated with ESKD incidence in African Americans with CKD. Tracking temporal changes in uric acid improves the assessment of ESKD risk in CKD progression.
引用
- Lee Y, Lipkowitz MS, Kopp JB, et al. Uric Acid Trajectories and CKD Progression in the African American Study of Kidney Disease and Hypertension. Kidney Int Rep. 2025. PMID: 41278313. doi:10.1016/j.ekir.2025.08.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。